A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Summary

This is a prospective, single-arm, open-label Phase 1 dose-finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the cell-based LCAR-C18S (hereinafter "LCAR-C18S") in subjects with Claudin18.2-positive advanced solid Tumors.

Timeline

Start

2020-09-21

Primary completion

2023-07-17

Completion

2023-07-17

Outcome

Outcome not reported

Stopped: “Both the sponsors and collaborator are considering terminating the study”

Drugs

Indications

No indication recorded.